The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2021 | Outcomes of older myelofibrosis patients who receive allogeneic transplantation
Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clínico Universitario Valencia, Valencia, Spain, comments on the findings of a retrospective study investigating the outcomes of older patients with myelofibrosis who undergo allogeneic transplantation. Dr Hernández-Boluda reports that patients who received transplant had a 5-year overall survival rate of around 40%, and that in the long-term outcomes were better for patients who received transplant compared to conventional treatment, although there is increased mortality in the first couple of years post-transplant. Dr Hernández-Boluda also comments on sex-based differences in outcomes. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
Disclosures
Juan Carlos Hernández-Boluda, MD, PhD, has received advisory honoraria from BMS and AOP Pharma; travel support from Incyte and Pfizer; and speaker fees from Pfizer, Novartis and Incyte.
